Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.41 |
| ▸ | MIF | P14174 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 5/20 | 0.37 |
| ▸ | CTSA | P10619 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CCNC | P24863 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5773773 | 0.91 | FFAR4 (0.43) | FFAR4MIFGABRA5CTSAMEN1 | |
| SCHEMBL5772569 | 0.90 | MAPT (0.46) | FFAR4GABRA5MEN1MAPTKMT2A | |
| SCHEMBL5773644 | 0.86 | FFAR4 (0.48) | FFAR4TRPV1FFAR1 | |
| SCHEMBL5771214 | 0.84 | FFAR4 (0.39) | FFAR4MIFMAPK1GABRA5CCNC | |
| SCHEMBL5776310 | 0.83 | FFAR4 (0.55) | FFAR4GABRA5 | |
| SCHEMBL5776636 | 0.78 | SIRT2 (0.37) | FFAR4GABRA5TRPV1FFAR1ABL1 | |
| SCHEMBL5774132 | 0.78 | KMO (0.36) | MAPK1GABRA5TRPV1ABL1 | |
| SCHEMBL5773927 | 0.77 | CCNC (0.41) | MIFMAPK1MEN1KMT2ACCNC | |
| SCHEMBL5777241 | 0.76 | FFAR4 (0.51) | FFAR4FFAR1 | |
| SCHEMBL5775477 | 0.74 | RXRA (0.53) | FFAR4FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | MOMOSE YU | 2006-04-20 | — | — | US | disclosed |
| US-7022725-B2 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-04 | — | — | US | disclosed |
| US-20040048908-A1 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1340749-A1 | ISOXAZOLE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | INSR, GPR119, INSRR | FFAR4 143/4885MIF 3361/4885MAPK1 1148/4885 |
| US-20040048908-A1 | Isoxazole derivatives | GPR119, INSR, IRS1 | FFAR4 145/4885MIF 3127/4885MAPK1 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.